Cytotoxicity of Simvastatin in Human Breast Cancer MCF-7 and MDA-MB-231 Cell Lines

Rezano, Andri; Ridhayanti, Firda; Rangkuti, Athaya Riski; Gunawan, Taufik; Winarno, Gatot Nyarumenteng Adhipurnawan; Wijaya, Indra

doi:10.31557/apjcp.2021.22.s1.33

Cited by 23 publications

(15 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, the adverse effects of simvastatin are of concern as long-term administration of simvastatin may cause symptoms such as rhabdomyolysis and hepatotoxicity [ 49 ]. In view of this, the optimal clinical dose and duration of use needs to be determined to ensure patient safety [ 31 , 50 , 51 ].…”

Section: Discussionmentioning

confidence: 99%

Simvastatin in the Treatment of Colorectal Cancer: A Review

Zang

Yang

Tian

2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Drug repositioning and drug reuse are the heated topics in the field of oncology in recent years. These two concepts refer to seeking effective drugs for cancer that are not originally intended to treat cancer. The survival benefits are then analyzed by combining the re-positioned drugs with conventional cancer treatment methods. Simvastatin is a clinically commonly used hyperlipidemia drug and exerts the effect of preventing cardiovascular diseases. Recent studies have found that simvastatin has great potential in the treatment of colorectal cancer, and a large number of clinical studies have used simvastatin as an adjuvant drug to help treat metastatic colorectal cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Simvastatin in the Treatment of Colorectal Cancer: A Review

Zang

Yang

Tian

2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…Apoptotic effects were due to the increased expression of miR-140-5p in a dose-dependent manner mediated by the activating transcription factor NRF1 [65]. Apart from the MDA-MB-231 cell line, Simvastatin effects were also explored in other breast cancer cell lines such as T47D, BT-549, and MCF-7, showing apoptotic inducer anti-proliferative activity [66,67]. In in vivo studies with DMBA (dimethyl-Benz(a)anthracene) induced breast cancer rat model, Simvastatin reduced the tumor volume by around 80% [68].…”

Section: Simvastatinmentioning

confidence: 99%

Breast Cancer Drug Repurposing a Tool for a Challenging Disease

Malik¹,

Jan²,

Ahmed³

et al. 2022

Drug Repurposing - Molecular Aspects and Therapeutic Applications

View full text Add to dashboard Cite

Drug repurposing is one of the best strategy for drug discovery. There are several examples where drug repurposing has revolutionized the drug development process, such as metformin developed for diabetes and is now employed in polycystic ovarian syndrome. Drug repurposing against breast cancer is currently a hot topic to look upon. With the continued rise in breast cancer cases, there is a dire need for new therapies that can tackle it in a better way. There is a rise of resistance to current therapies, so drug repurposing might produce some lead candidates that may be promising to treat breast cancer. We will highlight the breast cancer molecular targets, currently available drugs, problems with current therapy, and some examples that might be promising to treat it.

show abstract

“…Despite widespread usage, less research has been conducted on the effects of atorvastatin on MCF7. Other statins such as simvastatin (Rezano et al 2020 ) and other lines such as triple-negative MDA-MB-231 cell line (Hu et al 2018 ) have further been investigated. On the other hand, several studies have postulated the mesenchymal stem cells (MSCs) just as safe, tumor-targeting cell-based therapy (Subramanian et al 2012 ).…”

Section: Introductionmentioning

confidence: 99%

Synergistic inhibitory effect of human umbilical cord matrix mesenchymal stem cells-conditioned medium and atorvastatin on MCF7 cancer cells viability and migration

et al. 2022

View full text Add to dashboard Cite

Graphical abstract Recent studies have demonstrated inhibitory effects of mesenchymal stem cells on breast tumors. Likewise, the emerging interest in statins as anticancer agents is based on their pleiotropic effects. In the present study, we investigated whether atorvastatin and umbilical cord matrix derived mesenchymal stem cells-conditioned medium affect the MCF7 cancer cells viability and interactions. We measured the viability of MCF7 cancer cells by MTT assay, flow cytometry, and quantitative real-time PCR. Two-dimensional culture and hanging drop aggregation assay illustrated the morphological changes. We traced the MCF7 migration via scratch-wound healing test and trans-well assay. The results showed the inhibition of cancer cell viability in all treated groups compared to the control group. The effect of atorvastatin and conditioned medium combination was significantly more than each substance separately. The morphological changes indicated apoptosis in treated cells. The annexin V/PI flow cytometry especially in the combination-treated group displayed decreasing in DNA synthesis and cell cycle arrest in G1 and G2/M phases. As well, the mRNA expressions of caspases 3, 8, 9, and Bcl-2 genes were along with extrinsic and intrinsic apoptosis pathways. Conditioned medium disrupted the connections between cancer cells, so the spheroids in three-dimensional configuration lost their order and dispersed. The migration of treated cells across the wound area and trans-well diminished, particularly by the conditioned medium and atorvastatin combination. There fore, the synergistic anti-proliferative and anti-motility effect of atorvastatin along with human umbilical cord mesenchymal stem cells-derived conditioned medium on MCF7 breast cancer cells have been proved. The results might lead the development of novel adjuvant anticancer therapeutics based on targeting or modifying the extracellular matrix to increase chemotherapy results or to prevent metastatic colonization. Schematic representation of “Synergistic Inhibitory Effect of Human Umbilical Cord Matrix Mesenchymal Stem Cells-Conditioned Medium and Atorvastatin on MCF7 Cancer Cells Viablity and Migration” by: Dr. Reyhaneh Abolghasemi, Dr. Somayeh Ebrahimi-barough, Proffesor. Jafar Ai.

show abstract

Cytotoxicity of Simvastatin in Human Breast Cancer MCF-7 and MDA-MB-231 Cell Lines

Cited by 23 publications

References 17 publications

Simvastatin in the Treatment of Colorectal Cancer: A Review

Simvastatin in the Treatment of Colorectal Cancer: A Review

Breast Cancer Drug Repurposing a Tool for a Challenging Disease

Synergistic inhibitory effect of human umbilical cord matrix mesenchymal stem cells-conditioned medium and atorvastatin on MCF7 cancer cells viability and migration

Contact Info

Product

Resources

About